Medicare's $35 insulin cap slashes costs for diabetes patients by over 50%
A new study by Johns Hopkins Bloomberg School of Public Health reveals a sharp drop in insulin costs for Medicare Part D patients. The research highlights how the $35 monthly cap, introduced under the Inflation Reduction Act, has eased financial pressure on diabetes management. Between 2019 and 2023, average out-of-pocket expenses for a 30-day insulin supply fell by more than half.
Before the policy change, Medicare beneficiaries paid an average of £50.87 for a 30-day insulin supply in 2019. By 2023, that figure had plummeted to £21.98. The study also found that the share of patients paying £35 or less jumped from 48% in 2019 to 75% in 2023.
Despite the progress, disparities remain. Around one in four beneficiaries still faced costs above £35 in 2023, largely due to prescription prorating issues. State-level variations in billing practices also contributed to uneven savings across the country.
Dr. Michael Fang, the study's lead author, stressed that Medicare's policy shifts have significantly improved insulin affordability. He noted that insulin's high cost had long hindered patient adherence and effective diabetes control. The federally enforced cap now provides stronger financial protections for millions of beneficiaries.
The $35 insulin cap has delivered measurable relief for most Medicare Part D enrollees. Yet gaps persist, with some patients still paying more than the limit due to billing complexities. Future research will focus on refining the system to ensure all beneficiaries fully benefit from the cost controls.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
